The median (95% CI) OS of patients with high tumor PLK5 protein expression was 61.0 (52.3–69.7) months, with a 3-year OS rate of 86.0% and a 5-year OS rate of 55.8%; the median (95% CI) OS of patients with low tumor PLK5 protein expression was 52.0 (47.6–56.4) months, with a 3-year OS rate of 75.2% and a 5-year OS rate of 30.2% in NSCLC patients (Figure 2B). This evidence concerns the gene PLK5 and neoplasm.